Advertisement

Pharmaceutisch Weekblad

, Volume 6, Issue 1, pp 27–31 | Cite as

Agents interfering with the platelet-vessel wall interaction

  • H. K. Nieuwenhuis
  • J. J. Sixma
Congress ‘Blood and Drugs’

Abstract

Drugs that inhibit platelet activation may prevent thrombosis and atherosclerosis. The mechanism by which coumarins, heparin, calmodulin inhibitors, calcium entry blockers, drugs that interfere with cyclic AMP function and arachidonate metabolism, and several other compounds might achieve this protection, is discussed. Only a few of these drugs (acetylsalicylic acid, dipyridamole, sulfinpyrazone) have been tested for clinical efficacy in man. So far the results of these studies have revealed modest protection from infarction and other cardiovascular diseases.

Keywords

Atherosclerosis Heparin Coumarin Clinical Efficacy Platelet Activation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sixma JJ. Role of blood vessel, platelet and coagulation interaction in haemostasis. In: Bloom AL, Thomas DP, eds. Haemostasis and Thrombosis. London: Churchill Livingstone, 1981:252–67.Google Scholar
  2. 2.
    Packham MA, Mustard JF. Pharmacology of platelet affecting drugs. Circulation 1980;62(suppl V):26–41.Google Scholar
  3. 3.
    Packham MA. Platelet function inhibitors. Thromb Haemostas 1983;50:610–9.Google Scholar
  4. 4.
    Moncada S, ed. Prostacyclin, thromboxane and leukotrienes. Br Med Bull 1983;39:209–300.Google Scholar
  5. 5.
    Weiss HJ. Platelets. Pathofysiology and antiplatelet drug therapy. New York: Alan R Liss, 1982:1–165.Google Scholar
  6. 6.
    May GS, Eberlein KA, Furberg CD, Passamani ER, DeMets DL. Secondary prevention after myocardial infarction: a review of long-term trials. Prog Cardiovasc Dis 1982;24:331–52.PubMedGoogle Scholar
  7. 7.
    Kelton JG. Antiplatelet agents: rationale and results. Clin Haematol 1983;12:311–54.PubMedGoogle Scholar
  8. 8.
    Gent M. The clinical evaluation of antiplatelet drugs. Recent Adv Blood Coag 1981;3:319–40.Google Scholar
  9. 9.
    Verstraete M. Registry of prospective clinical trials. Fifth report. Thromb Haemost 1982;48:334–8.PubMedGoogle Scholar
  10. 10.
    Verstraete M. Registry of prospective clinical trials. Sixth report. Thromb Haemost in press.Google Scholar
  11. 11.
    Persantine-Aspirin Reinfarction Study Research Group. Persantine and Aspirin in coronary heart disease. Circulation 1980;62:449–61.Google Scholar
  12. 12.
    Anturane Reinfarction Trial Research Group. Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med 1980;302:250–6.Google Scholar
  13. 13.
    Anturane Reinfarction Italian Study Group. Sulphinpyrazone in post-myocardial infarction. Lancet 1982; 1:237–42.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1984

Authors and Affiliations

  • H. K. Nieuwenhuis
    • 1
  • J. J. Sixma
    • 1
  1. 1.Department of HaematologyUniversity Hospital UtrechtGV UtrechtThe Netherlands

Personalised recommendations